-
Product Insights
NewLikelihood of Approval Analysis for Endocrine Gland Disorders
Overview How likely is it that the drugs in Endocrine Gland Disorders will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Endocrine Gland Disorders Overview Endocrine gland disorders are medical conditions that...
-
Product Insights
NewLikelihood of Approval Analysis for Pituitary Gland Disorders
Overview How likely is it that the drugs in Pituitary Gland Disorders will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pituitary Gland Disorders Overview Pituitary gland disorders involve dysregulation of the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pasireotide in Medullary Thyroid Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pasireotide in Medullary Thyroid Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pasireotide in Medullary Thyroid Cancer Drug Details: Pasireotide (Signifor, Upelior) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pasireotide in Hypoglycemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pasireotide in Hypoglycemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pasireotide in Hypoglycemia Drug Details: Pasireotide (Signifor, Upelior) is a synthetic polypeptide analogue...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Relacorilant in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Relacorilant in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Relacorilant in Triple-Negative Breast Cancer (TNBC) Drug Details: Relacorilant (CORT-125134)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Mifepristone in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mifepristone in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mifepristone in Non-Small Cell Lung Cancer Drug Details: Mifepristone (Korlym)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mifepristone in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mifepristone in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mifepristone in Triple-Negative Breast Cancer (TNBC) Drug Details: Mifepristone...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Relacorilant in Metastatic Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Relacorilant in Metastatic Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Relacorilant in Metastatic Ovarian Cancer Drug Details: Relacorilant (CORT-125134) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Relacorilant in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Relacorilant in Prostate Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Relacorilant in Prostate Cancer Drug Details: Relacorilant (CORT-125134) is under development...